MONOCLONAL ANTIBODIES TO MELANOMA-ASSOCIATED ANTIGENS

黑色素瘤相关抗原的单克隆抗体

• 批准号: 3175997
• 负责人: INGEGERD E HELLSTROM
• 金额: $ 20.93万
• 依托单位: ONCOGEN
• 依托单位国家: 美国
• 财政年份: 1984
• 资助国家: 美国
• 起止时间: 1984-08-01 至 1989-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3175997
• 关键词: active immunization; antiantibody; antiidiotype antibody; biopsy; cell mediated cytotoxicity; embryo /fetus antigen; gangliosides; gene expression; genetic manipulation; genetic recombination; human tissue; metastasis; monoclonal antibody; neoplasm /cancer classification /staging; neoplasm /cancer immunology; neoplasm /cancer immunotherapy; neoplasm /cancer transplantation; passive immunization; proteoglycan; tumor antigens; xenotransplantation

We plan to continue our monoclonal antibody studies on human melanomas towards the development of pre-clinical immunotherapeutical procedures for melanoma. There are 4 Specific Aims: 1. To continue our characterization of cell surface antigens of human melanomas by using monoclonal mouse antibodies. Our major effort will go into obtaining antibodies to antigens expressed by (malignant) melanoma but not by (benign) nevi. As part of this project, we shall look for antibodies distinguishing the two major subtypes of melanoma (nodular, superficial spreading) and - to the extent logistically possible - for antibodies distinguishing primary and metastatic melanoma. We shall also investigate the extent to which various melanoma-associated antigens (p97, a proteoglycan, a GD3 ganglioside, as well as the "new" antigens identified under Aim #1) are expressed in cells from human fetuses. 2. To obtain anti-idiotypic antibodies to human melanomas by using monoclonal mouse antibodies as immunogens and to use these antibodies to probe the immunological repertoire of melanoma patients; under Aim #4 the antibodies will also be used as immunogens in mice. 3. To test the ability of anti-melanoma antibodies to destroy human melanomas xenografted to nude mice. The effect of antibody alone, and antobody combined with an immunomodulator (e.g., BCG or C-parvum) will be investigated as part of this. 4. To use a model, in which the genes for p97 or the proteoglycan antigen are inserted into mouse tumor cells, to study anti-tumor effects, first, of passive immunization with anti-p97 antibody and, second, of active immunization with cells, antigens or anti-idiotypic antibodies.

我们计划继续对人黑色素瘤的单克隆抗体研究 为开发临床前免疫治疗程序 黑色素瘤。 有4个具体目标： 1。继续我们对人的细胞表面抗原的表征 黑色素瘤使用单克隆小鼠抗体。 我们的主要努力将继续 获得对（恶性）黑色素瘤表达的抗原的抗体，但 不是（良性）nevi。 作为该项目的一部分，我们将寻找 抗体区分黑色素瘤的两个主要亚型（结节性， 表面扩散）和 - 在逻辑上可能的范围内 - 区分原发性和转移性黑色素瘤的抗体。 我们也将 研究各种黑色素瘤相关抗原的程度（p97， 蛋白聚糖，gd3神经节苷脂以及确定的“新”抗原 在AIM＃1下）在人类胎儿的细胞中表达。 2。使用使用 单克隆小鼠抗体作为免疫原子，并使用这些抗体 探测黑色素瘤患者的免疫学库；在AIM＃4下 抗体也将用作小鼠的免疫原。 3。测试抗黑色瘤抗体破坏人的能力 黑色素瘤异种移植到裸鼠。 仅抗体的作用， 与免疫调节剂（例如BCG或C-Parvum）结合的Antobodo将是 作为其中的一部分进行了调查。 4。使用模型，其中P97或蛋白聚糖抗原的基因 被插入小鼠肿瘤细胞中，以研究抗肿瘤作用，首先 用抗P97抗体被动免疫，其次是活性的 用细胞，抗原或抗IDiotypic抗体进行免疫。